Private Label Peptides GuidesPrivate Label Peptides

What Belongs on the Label of a Private Label Research Peptide

By · Published

One federal rule, 21 CFR 312.160, prescribes a caution statement for a drug shipped under that section solely for tests in vitro or in laboratory research animals: “CAUTION: … Not for use in humans.” Other drug labeling rules also set label content for a drug within their scope; for example, 21 CFR 201.1 requires the label of a drug in finished package form to “bear conspicuously the name and place of business of the manufacturer, packer, or distributor,” and a named distributor’s name to be qualified by a phrase such as “Manufactured for ______”. This guide does not say whether 312.160 or 201.1 applies to a given product. The table below is practice agreed in writing between brand and manufacturer, not a list of what any rule requires. A sound label identifies the product as sold, states its quantity and a lot number that ties to the lot certificate of analysis (COA), says in plain words that it is for research use only and not for human or veterinary use, gives storage wording, and names the brand owner with a way to reach it.

This guide is for owners and procurement staff at research-use-only (RUO) peptide brands that buy finished product under a private label arrangement. It separates what a label should carry as practice, what the federal texts say, and who owns the wording. It is not legal advice.

What belongs on the label?

Element Why it is there Note
Product identity as sold The buyer must be able to tell what is in the vial Use the name on the product record and the COA, spelled the same way
Quantity or fill States what the vial holds Match the unit and the figure on the product record
Lot number Ties the vial to one lot record and one COA Check it traces to the lot COA
Research-use-only statement States the intended buyer and use Plain words, prominent. A brand shipping under 21 CFR 312.160 uses that section’s caution statement verbatim and must also meet the section’s other conditions; this guide does not say whether the section applies to a given product
“Not for human or veterinary use” wording Says what the product is not for Pair it with the RUO statement; do not replace it
Storage and handling wording Tells the lab how to keep it Words only, such as “store as directed on the product record”; no temperatures or time spans unless the manufacturer’s stability data supports them
Brand owner name and contact Says who is responsible and who to call A business name and a monitored contact; for a drug within its scope, 21 CFR 201.1 also sets the form of the name (paragraph (g)) and of the place of business (paragraph (i))
Manufactured-for wording Shows the brand owner is not the maker 21 CFR 201.1(h)(5) lists the qualifying phrases for a named distributor of a drug within its scope, including “Manufactured for ______”; agree the exact form with the manufacturer

Two limits apply to every row: print nothing the product record cannot back up, and keep every line readable at the printed size.

Is there a federal rule that sets the wording?

Federal texts set label wording for the drugs within their scope; this guide does not say whether any applies to a given product. Four federal texts bear on the question.

21 CFR 312.160(a)(1)(i) says “A person may ship a drug intended solely for tests in vitro or in animals used only for laboratory research purposes if it is labeled as follows: CAUTION: Contains a new drug for investigational use only in laboratory research animals, or for tests in vitro. Not for use in humans.” Section 312.2(b)(3) says “A drug intended solely for tests in vitro or in laboratory research animals is exempt from the requirements of this part if shipped in accordance with § 312.160.” “This part” is 21 CFR part 312, Investigational New Drug Application; the paragraph names no other requirement. Under (a)(2), a person shipping a drug under it “shall use due diligence to assure that the consignee is regularly engaged in conducting such tests and that the shipment of the new drug will actually be used for tests in vitro or in animals used only for laboratory research.” Under (a)(3), the shipper “shall maintain adequate records showing the name and post office address of the expert to whom the drug is shipped and the date, quantity, and batch or code mark of each shipment and delivery,” and records of shipments under (a)(1)(i) are kept for 2 years after the shipment. Under (c), the shipper “shall assure the return of all unused supplies of the drug from individual investigators whenever the investigation discontinues or the investigation is terminated,” and may authorize in writing an alternative disposition of unused supplies that “does not expose humans to risks from the drug, either directly or indirectly,” keeping records of it. Paragraph (a)(1)(i) covers a drug intended solely for tests in vitro or in animals used only for laboratory research purposes; paragraph (a)(1)(ii) separately covers certain biological products for investigational in vitro diagnostic use. For that drug the section prescribes one statement and does not set the rest of a label’s content, and printing the statement does not by itself meet the section’s other conditions.

21 CFR 201.1 sets name and place of business wording for drug labels. Paragraph (a) says a drug or drug product in finished package form is misbranded if its label does not “bear conspicuously the name and place of business of the manufacturer, packer, or distributor,” and does not apply to a drug dispensed in accordance with section 503(b)(1) of the act. Paragraph (h)(5) says “If the distributor is named on the label, the name shall be qualified by one of the following phrases: “Manufactured for ______”, “Distributed by ______”, “Manufactured by ______ for ______”, “Manufactured for _____by _____”, “Distributor: ______”, “Marketed by ______”.”

21 CFR 201.125 exempts a drug subject to 201.100 or 201.105 from section 502(f)(1) of the Federal Food, Drug, and Cosmetic Act “if shipped or sold to, or in the possession of, persons regularly and lawfully engaged in … research not involving clinical use, or in chemical analysis, or physical testing, and is to be used only for such … research, analysis, or testing.” It turns on who receives the product and what it is used for, not on a phrase printed on a vial; it does not mention research peptides and gives no label wording.

The RUO phrase appears in 21 CFR 809.10(c)(2)(i). It applies to in vitro diagnostic products. It exempts a shipment of such a product for an investigation that is not subject to part 812 from the IVD labeling requirements in 809.10(a) and (b) if the product is “in the laboratory research phase of development, and not represented as an effective in vitro diagnostic product,” and “all labeling bears the statement, prominently placed: “For Research Use Only. Not for use in diagnostic procedures.”” Section 809.10 covers in vitro diagnostic products, which 21 CFR 809.3(a) defines as “reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions”; this guide quotes 809.10(c)(2)(i) only as a model of how a plain, prominent research statement reads.

What should a label or listing never say?

Keep these off the label, listing, website and sales messages:

  • Benefit or performance claims of any kind.
  • Directions for preparing or using a product on a person.
  • Wording that points to individual consumption.
  • Wording that names or implies human or veterinary use.
  • Claims about testing or origin that the records on file cannot support.

The reason for the first four items is 21 CFR 201.128. It says intended use refers to “the objective intent of the persons legally responsible for the labeling of an article (or their representatives).” It adds that this intent “may be shown by such persons’ expressions, the design or composition of the article, or by the circumstances surrounding the distribution of the article,” for example “by labeling claims, advertising matter, or oral or written statements by such persons or their representatives.” It shows how FDA reads intent, and is why a research statement on a label does not settle the question alone.

Who is responsible for the label content?

The brand owner. The brand puts its name on the product, approves the wording and controls its listings, so the statements are the brand’s. The manufacturer prints and applies what was approved, controls the label master and tells the brand about any change on its side. 21 CFR 201.128 also says that if “a packer, distributor, or seller intends an article for different uses than those intended by the person from whom he or she received the article, such packer, distributor, or seller is required to supply adequate labeling in accordance with the new intended uses.” A brand owner’s own intent counts separately from its supplier’s.

Put the split in the quality agreement. State who drafts, approves, prints and applies label text, who holds the masters and who may change them. Writing the split down divides the work; it does not move the brand’s responsibility for its own statements to someone else. 21 CFR 201.128 also says objective intent may be shown “by circumstances in which the article is, with the knowledge of such persons or their representatives, offered or used for a purpose for which it is neither labeled nor advertised”.

How should approval and change control work?

Treat the label like any controlled document.

  1. Proof first. The manufacturer supplies a proof before any print run.
  2. Written sign-off. A named person at the brand approves the proof in writing. A chat reply is a weak record; use a signed or dated approval.
  3. Lot-tie check. Before release, compare the lot number on the label to the lot record and the COA for that lot. A mismatch means the lot waits.
  4. Label master control. Only the approved master is printed. The manufacturer version-controls it and does not edit it without approval.
  5. Change log. Every change gets a version, date, reason and approver. Keep old versions and the record of which lots carried which.
  6. Stop rule. If wording from a marketing or sales team conflicts with the approved master, the conflict goes back through the same approval path before anything changes.

Why should the label, the listing and the website agree?

Because under 21 CFR 201.128 intent can be read from any of them, not from the label alone. It can also be shown by the circumstances of distribution. Compare these before launch and after every change:

  • Product name and description on the label, the listing, the site and the COA.
  • The RUO and “not for human or veterinary use” wording on the label, the listing and the order or checkout pages.
  • Any image, caption or customer-facing message that shows or suggests use on a person.
  • Who the brand says it sells to, and how it checks that.

Assign one person to own this check, and keep dated copies of what was live.

Private Label Peptides offers private label and white label labels designed, printed and applied in-house. Every lot is tested by an independent third-party laboratory and has its own COA, and PLP attaches the laboratory’s report unchanged.

Last reviewed: 2026-11-13

References

Frequently asked questions

Is there a federal rule that sets the wording of a research peptide label?

One federal rule, 21 CFR 312.160, prescribes a caution statement for a drug shipped under that section solely for tests in vitro or in laboratory research animals: "CAUTION: ... Not for use in humans." Other drug labeling rules also set label content for a drug within their scope; for example, 21 CFR 201.1 requires the label of a drug in finished package form to "bear conspicuously the name and place of business of the manufacturer, packer, or distributor," and a named distributor's name to be qualified by a phrase such as "Manufactured for ______". This guide does not say whether 312.160 or 201.1 applies to a given product. The table below is practice agreed in writing between brand and manufacturer, not a list of what any rule requires.

Who is responsible for what the label says, the brand or the manufacturer?

The brand owner owns its own label content and marketing. A quality agreement can say who writes, approves, prints and applies the label, but it does not change whose statements they are.

Should the label, the product listing and the website say the same thing?

Yes. Because under 21 CFR 201.128 intent can be shown by statements and circumstances beyond the label, any difference between the three is a risk.